These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3913048)

  • 41. Postmarketing studies of drug efficacy: when must they be randomized?
    Strom BL; Miettinen OS; Melmon KL
    Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430
    [No Abstract]   [Full Text] [Related]  

  • 42. [Presentation of data in drug surveillance and bases for a decision].
    Lagier G
    Rev Med Interne; 1986 Nov; Spec No():41-4. PubMed ID: 3809779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-marketing surveillance of new drugs.
    Buckley EG
    J R Coll Gen Pract; 1987 Aug; 37(301):337-8. PubMed ID: 3448222
    [No Abstract]   [Full Text] [Related]  

  • 44. Yellow cards and green forms.
    Inman WH
    Practitioner; 1983 Sep; 227(1383):1443-9. PubMed ID: 6647229
    [No Abstract]   [Full Text] [Related]  

  • 45. [Industrial drug-surveillance].
    Juillet Y
    Rev Med Interne; 1986 Nov; Spec No():29-34. PubMed ID: 3809777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postmarketing surveillance methodologies.
    Edlavitch SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 48. A study of sterilization containers.
    Kneedler JA; Gattas M
    J Healthc Mater Manage; 1988; 6(4):24-8, 30. PubMed ID: 10287651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 51. A potential use of the National Death Index for postmarketing drug surveillance.
    Edlavitch SA; Feinleib M; Anello C
    JAMA; 1985 Mar; 253(9):1292-5. PubMed ID: 3968855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drug surveillance. Establishment of a benefit/risk ratio in current practice].
    Demarez JP; Couzinier JP; Begaud B
    Therapie; 1985; 40(5):333-5. PubMed ID: 4095691
    [No Abstract]   [Full Text] [Related]  

  • 53. EDPS of clinical case record and scientific document in the industry post-marketing surveillance of drugs.
    Kitaguchi T; Nojiri T; Suzuki S; Fukita T; Kawana T
    Methods Inf Med; 1983 Jul; 22(3):135-48. PubMed ID: 6633266
    [No Abstract]   [Full Text] [Related]  

  • 54. [Industrial drug-surveillance. Spontaneous notification: data collection, survey].
    Trunet P
    Rev Med Interne; 1986 Nov; Spec No():35-9. PubMed ID: 3809778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of record linkage in post-marketing drug surveillance.
    Crombie IK
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):77S-82S. PubMed ID: 3567036
    [No Abstract]   [Full Text] [Related]  

  • 56. Adverse reactions to new drugs.
    Venning GR
    Br Med J (Clin Res Ed); 1983 Mar; 286(6370):1052-3. PubMed ID: 6403183
    [No Abstract]   [Full Text] [Related]  

  • 57. [Problems of the number of cases in drug surveillance].
    Auriche M
    Rev Med Interne; 1986 Nov; Spec No():45-51. PubMed ID: 3809780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Better reporting of adverse drug reactions.
    Abrutyn E
    Ann Intern Med; 1985 Feb; 102(2):264-5. PubMed ID: 3966766
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluating and monitoring the safety and efficacy of drug therapy and surgery.
    Stolley PD; Strom BL
    J Chronic Dis; 1986; 39(12):1145-55. PubMed ID: 3539972
    [No Abstract]   [Full Text] [Related]  

  • 60. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
    Ball D
    Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.